IBRX vs KRYS: which is the better buy in 2026?
ImmunityBio, Inc.
NASDAQ:IBRX
Anktiva is quietly building a bladder cancer monopoly while 34% short interest stays anchored to a cash-burn story that no longer fits.
Full IBRX analysisKrystal Biotech, Inc.
NASDAQ:KRYS
VYJUVEK is the proof of concept that gene therapy works as a topical, repeatable product. The pipeline is the real prize.
Full KRYS analysisFactor by factor
Get head-to-heads like this, free
Join the Alexandria e-letter for Compass verdicts, earnings intelligence, and the contrarian calls the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is IBRX or KRYS the better buy in 2026?
IBRX and KRYS are neck and neck at 90/100 on the Compass right now. The better fit depends on which factors matter most to you.
How does Alexandria compare IBRX and KRYS?
Each company is scored 1-100 on eight factors: revenue growth, profitability, valuation, momentum, theme purity, moat, catalysts, and market position. The Compass Score is the composite, and the comparison below shows where each name wins factor by factor.
Compass Scores are proprietary editorial research from publicly available data, not investment advice or a recommendation regarding any security. Rankings update weekly.